# Hoth Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Hoth Therapeutics, Inc.). ## Overview Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for unmet medical needs across oncology supportive care, mast-cell disorders, neuroinflammation, dermatology, respiratory disease, and obesity-related conditions. The company has not commercialized any products and is still funding preclinical and clinical development of candidates such as HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, and HT-VA. ## Products & services • HT-001 topical therapy for cancer-treatment side effects • HT-KIT for mast-cell cancers and anaphylaxis • HT-ALZ for Alzheimer’s and neuroinflammatory diseases • BioLexa for atopic dermatitis (eczema) • HT-004 inhaled therapy for asthma and allergies • HT-VA for obesity and obesity-related diseases - **Oncology supportive care** (25%) — Therapies intended to reduce side effects from cancer treatments, centered on HT-001. - **Rare disease and immunology** (35%) — Programs targeting mast-cell cancers, anaphylaxis, eczema, asthma, and allergies. - **Neuroinflammation and CNS** (20%) — Development-stage assets aimed at Alzheimer’s disease and related neuroinflammatory conditions. - **Metabolic disease** (20%) — Obesity and obesity-related disease programs, primarily HT-VA. - HT-001 topical formulation for side effects from cancer drugs - HT-KIT for mast-cell derived cancers and anaphylaxis - HT-ALZ for Alzheimer’s and other neuroinflammatory diseases - BioLexa for atopic dermatitis (eczema) - HT-004 inhalational treatment for asthma and allergies - HT-VA for obesity and obesity-related diseases ## Customers Hoth Therapeutics does not yet sell commercial products, so its current “customers” are primarily research partners, licensors, clinical investigators, and future patients and prescribers if development succeeds. Its pipeline is aimed at distinct end markets: oncology supportive care, allergy/immunology, dermatology, neurology, and metabolic disease. The company’s near-term value creation depends on advancing these programs through preclinical and clinical milestones and securing external funding or partnerships. - **Future patients and prescribers** (primary) — Would use HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, or HT-VA if approved; demand is driven by unmet medical need. - **Clinical investigators and trial sites** (primary) — Run studies for the company’s pipeline and generate the data needed for regulatory advancement. - **Licensing and research partners** (secondary) — Provide sponsored research, option, sublicense, or collaboration support and may fund development. - **Institutional and retail capital markets** (primary) — Provide equity and debt financing because the company has no product revenue and ongoing cash burn. - Future patients needing treatment for cancer-drug side effects - Future patients with mast-cell cancers or anaphylaxis risk - Future patients with eczema, asthma, or allergies - Future patients with Alzheimer’s or neuroinflammatory disease - Research and licensing partners supporting development programs ## Geography Hoth Therapeutics is based in the United States and its reported disclosures are U.S.-centric, including reimbursement, healthcare reform, and financing references. The company has not disclosed meaningful country-level revenue because it has not commercialized products, so geographic exposure is mainly tied to U.S. clinical development, regulation, and future reimbursement. Its operating footprint is therefore concentrated in the U.S., with any future commercialization likely to depend on U.S. market access and payer coverage. - Headquartered in the United States - Clinical and regulatory exposure is primarily U.S.-based - No product sales revenue disclosed to date - Future commercialization would depend on U.S. payer coverage - No country-level revenue breakdown disclosed ## Strategy The company’s strategy is to advance a diversified pipeline of early-stage assets across several therapeutic areas rather than rely on a single program. Near-term priorities are preclinical and clinical development, preserving liquidity, and using partnerships or financing to support ongoing R&D. Because it has no commercial products, execution risk is concentrated in proving clinical value and obtaining capital on acceptable terms. - **Advance lead pipeline assets through development milestones** (short-term) — Clinical proof is the main driver of valuation and partnering interest for a pre-revenue biotech. - **Secure external financing and strategic partnerships** (short-term) — The company has no product revenue and ongoing operating losses, so funding is required to continue development. - **Broaden optionality across multiple therapeutic areas** (medium-term) — A multi-asset pipeline reduces dependence on any single program and increases the chance of a value-creating outcome. - Advance HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, and HT-VA - Use preclinical and clinical milestones to de-risk the pipeline - Seek partnerships, sublicenses, or strategic collaborations - Preserve cash while funding R&D and development overhead - Build future commercialization optionality across multiple indications ## Risks Hoth Therapeutics is exposed to the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need for repeated financing before any product revenue exists. The company also faces reimbursement and pricing pressure if programs are commercialized, plus dilution risk from equity issuance and stock-based compensation. Because development is early and cash burn continues, execution on funding and trial progress is critical to survival. - **No product commercialization** [critical] — The company has never generated revenue from product sales, so it depends on capital markets and development success. - **Clinical and regulatory failure** [high] — Pipeline assets are preclinical/clinical-stage and may not demonstrate safety or efficacy. - **Financing and dilution risk** [high] — The company has recurring operating losses and will need additional funding to continue development. - **Reimbursement and pricing pressure** [medium] — Medicare and private payor policies can reduce future pricing and coverage for approved drugs. - **Contractual milestone and royalty obligations** [medium] — License and sponsored research agreements may require milestone, royalty, and maintenance payments. - No commercial products and no product revenue to date - Clinical trial failure could eliminate pipeline value - Additional financing may be unavailable or highly dilutive - Healthcare reimbursement reforms could pressure future pricing - License agreements may require milestones, royalties, and fees ## Accounting The most important accounting issues are typical for a pre-revenue biotech: stock-based compensation, fair value estimates, and the treatment of financing instruments such as warrants. Because the company has no product revenue, investors should focus on expense recognition, cash burn, and whether development costs and collaboration obligations are being reflected appropriately. Management also relies on judgment in valuing equity awards and estimating the company’s ability to continue as a going concern. - **Stock-based compensation** — Reported operating loss and EPS - **Fair value of warrants and equity instruments** — Capital structure and dilution - **Going-concern and liquidity assessment** — Disclosure and investor risk assessment - **License and milestone obligations** — Future cash outflows and contingent liabilities - Stock-based compensation affects reported operating expenses - Black-Scholes assumptions drive option valuation - Warrant exercises and equity issuance affect capital structure - No product revenue means expense trends dominate results - Going-concern and liquidity judgments are important --- *Last updated: 2026-04-28T20:15:06.090077+00:00*